David P. Bonita
David P. Bonita's purchase track record
How the stock did after each of David P. Bonita's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 4/21/2026 | PRLD | $12.50M | -12.6% | pending | — |
| 7/25/2025 | IMA | $2.50M | -53.4% | -57.9% | +8.3% |
| 5/22/2023 | PRLD | $5.00M | -38.9% | -37.1% | +8.5% |
| 6/22/2022 | IMA | $1.13M | +3.8% | -28.1% | +3.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
ImageneBio Reports Inducement Grants Under Nasdaq Rule. ImageneBio has disclosed new inducement grants in compliance with Nasdaq Listing Rule 5635(c)(4). This filing is a standard corporate disclosure regarding compensation and does not report new clinical data or financial results. The stock is currently trading within its 52-week range, with an average analyst target of $18.00.
Transaction History
| PRLD | ▲ Buy | Open Market | 1,689,189 | $7.5M | 4/21/2026 | View on chart |
| PRLD | ▲ Buy | Open Market | 1,126,126 | $5.0M | 4/21/2026 | View on chart |
| IMA | ▲ Buy | Option Exercise | 379 | — | 7/25/2025 | View on chart |
| IMA | ▲ Buy | Open Market | 83,611 | $2.5M | 7/25/2025 | View on chart |
| IMA | ▲ Buy | Grant | 153,121 | — | 8/4/2023 | View on chart |
| PRLD | ▲ Buy | Open Market | 869,565 | $5.0M | 5/22/2023 | View on chart |
| IMA | ▲ Buy | Open Market | 96,035 | $516K | 6/24/2022 | View on chart |
| IMA | ▲ Buy | Open Market | 65,965 | $288K | 6/24/2022 | View on chart |
| IMA | ▲ Buy | Open Market | 23,419 | $87K | 6/23/2022 | View on chart |
| IMA | ▲ Buy | Open Market | 66,806 | $237K | 6/22/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
PRLD announces collaboration and supply deal with Eli Lilly
Prelude Therapeutics disclosed a collaboration and supply agreement with Eli Lilly. The arrangement will have Prelude provide its CDK4/6 inhibitor abemaciclib and oral estrogen receptor antagonist imlunestrant for Lilly‑led clinical trials. Partnering with a large pharmaceutical company may expand Prelude's development pipeline and potential revenue sources. The stock is currently near its long‑term support level.
PRLD announces collaboration and supply deal with Eli Lilly. Prelude Therapeutics disclosed a collaboration and supply agreement with Eli Lilly. The arrangement will have Prelude provide its CDK4/6 inhibitor abemaciclib and oral estrogen receptor antagonist imlunestrant for Lilly‑led clinical trials. Partnering with a large pharmaceutical company may expand Prelude's development pipeline and potential revenue sources. The stock is currently near its long‑term support level.